Does EDCF contribute to diabetic endothelial cell dysfunction?

Dialogues in Cardiovascular Medicine

Volumn 7, Issue 4, 2002, Pages 225-231

  Cohen, Richard A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; EDCF; Endothelium; Nitric oxide; Oxidant stress; Prostacyclin; TP receptor

Indexed keywords

CELL ADHESION MOLECULE; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; FREE RADICAL; GLUCOSE; ICOSANOID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGEN; PEROXYNITRITE; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; PROSTANOID RECEPTOR; SCAVENGER; THROMBOXANE RECEPTOR;

ARTICLE; ATHEROSCLEROSIS; CELL DAMAGE; CELL DEATH; DIABETES MELLITUS; DIABETIC ANGIOPATHY; ENDOTHELIUM CELL; ENZYME INACTIVATION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; THROMBOSIS; VASOCONSTRICTION; VASODILATATION;

EID: 0038266244     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ross R, Agius L. The process of atherogenesis-cellular and molecular interaction: from experimental animal models to humans. Diabetologia. 1992;35:s34-s4O.
2. Cohen RA. Endothelial dysfunction in diabetic vascular disease. Medicographia. 1997;19:157-161.
3. Veves A, Akbari CM, Primavera J, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes. 1998;47:457-463.
4. Egan BM, Lu G, Greene EL. Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster. Prostaglandins Leukot Essent Fatty Acids. 1999;60:411-420.
5. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998;97:1695-1701.
6. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation. 2002;105:1567-1572.
7. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest. 2002;109:817-826.
8. Cohen RA. Nitric oxide bioavailability and diabetic endothelial cell dysfunction. In: Tooke JE, ed. Vascular Disease in Diabetes. A Report of the Hemovascular Study Group. Kent, UK: Wells Healthcare Communications Limited; 2001:87-106.
9. 2. Am J Physiol. 1989;257:H1327-H1333.
10. Tesfamariam B, Brown ML, Deykin D, Cohen RA. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest. 1990;85:929-932.
11. Cohen RA, Pagano PJ. Other factors in endothelial cell dysfunction in hypertension and diabetes. In: Vallance P, Webb D, eds. Endothelial Function in Hypertension. Berlin, Germany: Springer Verlag; 1997: 39-51.
12. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest. 1991;87:1643-1348.
13. Tesfamariam B, Cohen RA. Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. Am J Physiol. 1992;31:H1915-H1919.
14. Tesfamariam B, Brown ML, Cohen RA. 15-Hydroxyeicosatetraenoic acid and diabetic endothelial dysfunction in rabbit aorta. J Cardiovasc Pharmacol. 1995;25: 748-755.
15. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol. 1992;263:H321-H326.
16. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1996;97:22-28.
17. 2 receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes. 2002;51:198-203.
18. Katusic ZS. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol. 2001;281:H981-H986.
19. Zou M, Jendral M, Ullrich V. Prostaglandin endoperoxide-dependent vasospasm in bovine coronary arteries after nitration of prostacyclin synthase. Br J Pharmacol. 1999;126:1283-1292.
20. Chen J, Kuhlencordt PJ, Astern J, Gyurko R, Huang PL. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein E/endothelial nitric oxide synthase double knockout mice. Circulation. 2001;104:2391-2394.
21. 2. Science. 2002;296:474-475.
22. 2 receptor antagonist, S18886, but not asprin, inhibits atherogenesis in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol. 1999;20: 1724-1728.
23. Cohen RA, Xu S, Maitland K, Cayatte AJ, Lavielle G, Verbeuren TJ. The TP receptor antagonist, S18886, prevents the enhancement of atherogenesis by diabetes mellitus in apolipoprotein E deficient mice. Circulation. 2001;104:II118.
24. Milani M, Longoni A, Maderna M. Effects of picotamide, an antiplatelet agent, on cardiovascular events, in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. Br J Clin Pharmacol. 1996;42:782-785.